{"nctId":"NCT02487446","briefTitle":"Efficacy and Safety Study of QVA149 in COPD Patients","startDateStruct":{"date":"2015-07-28","type":"ACTUAL"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":357,"armGroups":[{"label":"First QVA149, then Umeclidinium/vilanterol","type":"EXPERIMENTAL","interventionNames":["Drug: QVA149","Drug: Umeclidinium/vilanterol","Drug: Placebo (umeclidinium/vilanterol)","Drug: Placebo (QVA149)"]},{"label":"First Umeclidinium/vilanterol, then QVA149","type":"EXPERIMENTAL","interventionNames":["Drug: QVA149","Drug: Umeclidinium/vilanterol","Drug: Placebo (umeclidinium/vilanterol)","Drug: Placebo (QVA149)"]}],"interventions":[{"name":"QVA149","otherNames":["Indecaterol maleate/glycopyrronium bromide"]},{"name":"Umeclidinium/vilanterol","otherNames":["ELLIPTA®"]},{"name":"Placebo (umeclidinium/vilanterol)","otherNames":[]},{"name":"Placebo (QVA149)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female adults aged ≥40 yrs\n* Smoking history of at least 10 pack years\n* Diagnosis of stable Chronic Obstructive Pulmonary Disease (COPD) as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2015)\n* Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)\\< 80% and ≥ 30% of the predicted normal value and post-bronchodilator FEV1/FVC (forced vital capacity) \\<70%\n* Modified Medical Research Council questionnaire grade of 2 or higher\n\nExclusion Criteria:\n\n* Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1\n* Patients with concomitant pulmonary disease\n* Patients with a history of asthma\n* Any patient with lung cancer or a history of lung cancer\n* Patients with a history of certain cardiovascular co-morbid conditions\n* Patients with a known history and diagnosis of alpha-1 antitrypsin deficiency\n* Patients in the active phase of a supervised pulmonary rehabilitation program\n* Patients contraindicated for inhaled anticholinergic agents and β2 agonists\n* Other protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Forced Expiratory Volume (FEV1) Area Under the Curve (AUC) 0-24h","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 0-24h). A positive change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2321","spread":"0.01133"},{"groupId":"OG001","value":"0.2436","spread":"0.01130"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Forced Expiratory Volume (FEV1) Area Under the Curve (AUC) 0-24h","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over an entire day (AUC 0-24h). A positive change from baseline indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2321","spread":"0.01133"},{"groupId":"OG001","value":"0.2436","spread":"0.01130"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Trough FEV1 (Mean of 23h 15 Minutes and 23 h 45 Minutes Post Previous Morning Dose)","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 15 minutes and 23 hours 45 minutes post-dose for each treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1891","spread":"0.01070"},{"groupId":"OG001","value":"0.2043","spread":"0.01069"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FEV1 AUC 12-24h","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over 12 hours (AUC 12-24h).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2076","spread":"0.01159"},{"groupId":"OG001","value":"0.2025","spread":"0.01156"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FEV1 AUC 0-12h","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over 12 hours (AUC 0-12h).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2543","spread":"0.01031"},{"groupId":"OG001","value":"0.2848","spread":"0.01026"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FEV1 AUC 0-4h, AUC 4-8h, AUC 8-12h, AUC 12-16h, AUC 16-20h and AUC 20-24h","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time over 4 hour intervals FEV1 AUC 0-4h, AUC 4-8h, AUC 8-12h, AUC 12-16h, AUC 16-20h and AUC 20-24h.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3223","spread":"0.01087"},{"groupId":"OG001","value":"0.3289","spread":"0.01080"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2399","spread":"0.01051"},{"groupId":"OG001","value":"0.2831","spread":"0.01045"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1911","spread":"0.01069"},{"groupId":"OG001","value":"0.2411","spread":"0.01062"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2594","spread":"0.01241"},{"groupId":"OG001","value":"0.2349","spread":"0.01236"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1914","spread":"0.01247"},{"groupId":"OG001","value":"0.1875","spread":"0.01244"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1722","spread":"0.01136"},{"groupId":"OG001","value":"0.1821","spread":"0.01133"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pre-dose Trough FEV1 (Mean of 15 Minutes and 45 Minutes Pre Morning Dose)","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Pre-dose trough FEV1 was defined as the average of measurements made 15 minutes and 45 minutes pre morning dose for each treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2302","spread":"0.01138"},{"groupId":"OG001","value":"0.2450","spread":"0.01135"}]}]}]},{"type":"SECONDARY","title":"QVA149 Compared to Umeclidinium/Vilanterol in Terms of Change From Baseline in FEV1 at Any Time Point","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1112","spread":"0.01011"},{"groupId":"OG001","value":"0.1201","spread":"0.01007"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1509","spread":"0.01046"},{"groupId":"OG001","value":"0.1682","spread":"0.01048"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1602","spread":"0.01071"},{"groupId":"OG001","value":"0.1945","spread":"0.01073"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1755","spread":"0.01105"},{"groupId":"OG001","value":"0.2230","spread":"0.01100"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1840","spread":"0.01161"},{"groupId":"OG001","value":"0.2329","spread":"0.01157"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1432","spread":"0.01107"},{"groupId":"OG001","value":"0.2270","spread":"0.01105"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0815","spread":"0.01054"},{"groupId":"OG001","value":"0.1861","spread":"0.01056"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0699","spread":"0.01153"},{"groupId":"OG001","value":"0.1674","spread":"0.01138"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1498","spread":"0.01078"},{"groupId":"OG001","value":"0.1764","spread":"0.01063"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1579","spread":"0.01103"},{"groupId":"OG001","value":"0.1932","spread":"0.01090"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2122","spread":"0.01143"},{"groupId":"OG001","value":"0.2469","spread":"0.01141"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2378","spread":"0.01181"},{"groupId":"OG001","value":"0.2668","spread":"0.01179"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2225","spread":"0.01149"},{"groupId":"OG001","value":"0.2378","spread":"0.01146"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2390","spread":"0.01182"},{"groupId":"OG001","value":"0.2538","spread":"0.01179"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2879","spread":"0.01029"},{"groupId":"OG001","value":"0.2831","spread":"0.01027"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3187","spread":"0.01079"},{"groupId":"OG001","value":"0.3074","spread":"0.01074"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3346","spread":"0.01103"},{"groupId":"OG001","value":"0.3258","spread":"0.01091"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3426","spread":"0.01128"},{"groupId":"OG001","value":"0.3334","spread":"0.01119"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3343","spread":"0.01188"},{"groupId":"OG001","value":"0.3445","spread":"0.01175"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2760","spread":"0.01137"},{"groupId":"OG001","value":"0.3137","spread":"0.01126"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2033","spread":"0.01078"},{"groupId":"OG001","value":"0.2545","spread":"0.01071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1764","spread":"0.01189"},{"groupId":"OG001","value":"0.2311","spread":"0.01151"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2343","spread":"0.01257"},{"groupId":"OG001","value":"0.2218","spread":"0.01242"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2465","spread":"0.01291"},{"groupId":"OG001","value":"0.2324","spread":"0.01282"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2695","spread":"0.01307"},{"groupId":"OG001","value":"0.2350","spread":"0.01302"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2749","spread":"0.01305"},{"groupId":"OG001","value":"0.2448","spread":"0.01294"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2667","spread":"0.01331"},{"groupId":"OG001","value":"0.2355","spread":"0.01314"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2230","spread":"0.01306"},{"groupId":"OG001","value":"0.2197","spread":"0.01296"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1622","spread":"0.01281"},{"groupId":"OG001","value":"0.1629","spread":"0.01273"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1791","spread":"0.01095"},{"groupId":"OG001","value":"0.1981","spread":"0.01088"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2048","spread":"0.01122"},{"groupId":"OG001","value":"0.2117","spread":"0.01118"}]}]}]},{"type":"SECONDARY","title":"QVA149 Compared to Umeclidinium/Vilanterol in Terms of Change From Baseline in Forced Vital Capacity (FVC) at Any Time Point","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2177","spread":"0.01732"},{"groupId":"OG001","value":"0.2218","spread":"0.01726"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2566","spread":"0.01818"},{"groupId":"OG001","value":"0.2927","spread":"0.01821"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2811","spread":"0.01846"},{"groupId":"OG001","value":"0.3325","spread":"0.01849"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2944","spread":"0.01912"},{"groupId":"OG001","value":"0.3534","spread":"0.01904"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3109","spread":"0.01966"},{"groupId":"OG001","value":"0.3687","spread":"0.01960"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2788","spread":"0.04347"},{"groupId":"OG001","value":"0.4237","spread":"0.04339"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1681","spread":"0.01816"},{"groupId":"OG001","value":"0.3237","spread":"0.01818"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1406","spread":"0.01915"},{"groupId":"OG001","value":"0.2910","spread":"0.01889"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2565","spread":"0.01777"},{"groupId":"OG001","value":"0.2747","spread":"0.01753"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2737","spread":"0.01903"},{"groupId":"OG001","value":"0.3001","spread":"0.01883"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2914","spread":"0.01853"},{"groupId":"OG001","value":"0.3513","spread":"0.01851"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3390","spread":"0.01922"},{"groupId":"OG001","value":"0.3732","spread":"0.01919"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3044","spread":"0.01864"},{"groupId":"OG001","value":"0.3442","spread":"0.01859"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3344","spread":"0.01923"},{"groupId":"OG001","value":"0.3566","spread":"0.01919"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3960","spread":"0.01760"},{"groupId":"OG001","value":"0.3861","spread":"0.01756"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4378","spread":"0.01865"},{"groupId":"OG001","value":"0.4169","spread":"0.01857"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4602","spread":"0.01892"},{"groupId":"OG001","value":"0.4480","spread":"0.01875"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4649","spread":"0.01948"},{"groupId":"OG001","value":"0.4647","spread":"0.01934"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4405","spread":"0.02006"},{"groupId":"OG001","value":"0.4853","spread":"0.01987"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3872","spread":"0.04490"},{"groupId":"OG001","value":"0.4343","spread":"0.04435"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2714","spread":"0.01856"},{"groupId":"OG001","value":"0.3555","spread":"0.01844"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2306","spread":"0.01977"},{"groupId":"OG001","value":"0.3231","spread":"0.01911"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3455","spread":"0.02063"},{"groupId":"OG001","value":"0.3112","spread":"0.02038"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3409","spread":"0.02086"},{"groupId":"OG001","value":"0.3235","spread":"0.02070"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3688","spread":"0.02196"},{"groupId":"OG001","value":"0.3326","spread":"0.02187"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3760","spread":"0.02123"},{"groupId":"OG001","value":"0.3361","spread":"0.02104"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3681","spread":"0.02192"},{"groupId":"OG001","value":"0.3371","spread":"0.02162"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3129","spread":"0.02205"},{"groupId":"OG001","value":"0.3279","spread":"0.02189"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2175","spread":"0.02180"},{"groupId":"OG001","value":"0.2353","spread":"0.02167"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2237","spread":"0.01804"},{"groupId":"OG001","value":"0.2750","spread":"0.01792"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2607","spread":"0.01935"},{"groupId":"OG001","value":"0.2728","spread":"0.01928"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":341},"commonTop":["Chronic obstructive pulmonary disease","Nasopharyngitis","Upper respiratory tract infection","Bronchitis","Dyspnoea"]}}}